However, Gal‐SLPs exhibited much better antitumor efficiency, strongly suppressing the tumor growth during the whole experimental period, resulting in a tumor‐growth inhibition rate (TIR %) of 82.7 ± 4.9% in terms of tumor weight at the end of experiment, significantly higher than that of sorafenib (53.4 ± 15.5%) and Gal‐LPs (55.0 ± 7.8%) (Figure 7d,e, Figure S10, Supporting Information). This evidence concerns the gene GAL and neoplasm.